ATNM:NYE-Actinium Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 7.11

Change

-0.11 (-1.52)%

Market Cap

USD 0.22B

Volume

0.09M

Analyst Target

USD 70.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

-1.73 (-1.27%)

USD 612.29B
BHVN Biohaven Pharmaceutical Holdin..

-0.32 (-0.84%)

USD 3.61B
RCUS Arcus Biosciences Inc

-0.25 (-1.51%)

USD 1.58B
NUVB Nuvation Bio Inc

+0.03 (+1.01%)

USD 0.80B
DNA Ginkgo Bioworks Holdings

+0.14 (+2.30%)

USD 0.39B
ADCT ADC Therapeutics SA

+0.05 (+1.83%)

USD 0.27B
CYBN Cybin Inc

-0.01 (-3.03%)

USD 0.20B
ANVS Annovis Bio Inc

+0.06 (+0.72%)

USD 0.11B
ARMP Armata Pharmaceuticals Inc

+0.08 (+3.13%)

USD 0.09B
MAIA MAIA Biotechnology Inc.

+0.46 (+15.75%)

USD 0.07B

ETFs Containing ATNM

RJZ 0.00 % 0.75 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.96% 79% B- 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.96% 79% B- 95% A
Trailing 12 Months  
Capital Gain -0.56% 58% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.56% 55% F 25% F
Trailing 5 Years  
Capital Gain -0.84% 84% B 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.84% 74% C 31% F
Average Annual (5 Year Horizon)  
Capital Gain 14.07% 74% C 78% C+
Dividend Return 14.07% 74% C 74% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 117.43% 19% F 6% D-
Risk Adjusted Return 11.98% 61% D- 36% F
Market Capitalization 0.22B 74% C 34% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.